Indivior PLC (LON:INDV – Get Free Report)’s stock price fell 15.7% during trading on Friday . The company traded as low as GBX 548.71 ($6.95) and last traded at GBX 732 ($9.28). 1,888,371 shares were traded during trading, an increase of 166% from the average session volume of 709,477 shares. The stock had previously closed at GBX 868 ($11.00).
Wall Street Analyst Weigh In
Separately, Jefferies Financial Group reaffirmed a “buy” rating and set a GBX 1,800 ($22.81) price target on shares of Indivior in a research report on Tuesday, December 17th.
View Our Latest Analysis on Indivior
Indivior Price Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Stories
- Five stocks we like better than Indivior
- Top Stocks Investing in 5G Technology
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.